Global Gene Synthesis Sales Revenue Is Nearly 202 M USD In 2017
Monday, 22 Oct, 2018
In the last several years, global market of Gene Synthesis developed rapidly, with the CAGR (from 2013 to 2017) of 12.5%. In 2017, global sales revenue of Gene Synthesis is nearly 202 M USD; meanwhile the global market is expected to reach 562 M USD in the end of 2024.

Genescript is the largest supplier of Gene Synthesis, with a sales market share nearly 30% in 2017. That is to say, Genescript is the most popular Gene Synthesis in global, and with most of the Gene Synthesis market share in global. Again, top 6 players dominated 80% global gene synthesis market share’ total, with most of which were USA companies.

Despite Genscript was ranked #1 in global gene synthesis market, other sophisticated companies in the US and Europe may enter into this sector through M&A on smaller competitors to Genscript or buying related business from other market. This will result in reshuffling of the biomedicine research services’ market, and that Genscript may loss its market share.

The classification of Gene Synthesis includes below 1000 bp, 1001 - 3000?bp, 3001 – 5000 bp and Above 5000 bp. The proportion of 1000 – 3000 bp in 2017 is about 40%, the proportion of below 1000 bp in 2017 is about 26.1%, and the proportion of 3001 – 5000 bp in 2017 is about 22.85%.

North America is the largest consumption market, with a consumption market share nearly 40% in 2017. Followed by North America, Asia Pacific is the second largest consumption place with the consumption market share of 29.9%. 

Gene Synthesis is used for Commercial and Academic Research. Report data showed that 50.1 % of the Gene Synthesis market used of Academic Research in 2017.

Market competition is intense between top 5. Genescript, GeneArt (Thermofischer), IDT, DNA 2.0 (ATUM), OriGene are the top 5 leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.